Alzheimer's Research & Therapy

CORRECTION

Open Access

Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer's disease

Lawrence S. Honig[1*], Marwan N. Sabbagh[2], Christopher H. van Dyck[3], Reisa A. Sperling[4], Steven Hersch[5], Andre Matta[5], Luigi Giorgi[6], Michelle Gee[6], Michio Kanekiyo[5], David Li[5], Derk Purcell[7], Shobha Dhadda[5], Michael Irizarry[5] and Lynn Kramer[5]

Correction: ***Alz Res Therapy*** **16, 105 (2024)**
https://doi.org/10.1186/s13195-024-01441-8

Following publication of the original article [1], several typographical errors were observed:

- In Table 2, recurrent ARIA-E for ApoE carriers should be 3.8% (not 11.7%).
- In Table 2, there were several incorrect indentations for several rows (old and updated versions of Table 2 are presented below).
- There are two places on page 6 where 'ARIA-E' should be 'ARIA'.
- In Table 5, the asterisk in right column should be a superscript '1'. The footnote should have an end parenthesis at end of the footnote sentence below the table.

Moreover, Supplementary material 1 (.docx) has been replaced with its pdf version with modification in Table S4 - ID21 (the participant should be "male" instead of "female").

The online version of the original article can be found at https://doi.org/10.1186/s13195-024-01441-8.

*Correspondence:
Lawrence S. Honig
lh456@cumc.columbia.edu
[1]Columbia University Irving Medical Center, NYS Center of Excellence for Alzheimer's Disease, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Gertrude H. Sergievsky Center (PH19), & Department of Neurology, Columbia University Vagelos College of Physicians & Surgeons, 630 West 168th Street (P&S UNIT 16), New York, NY 10032-3795, USA
[2]Barrow Neurological Institute, Phoenix, AZ 85013, USA
[3]Yale School of Medicine, New Haven, CT, USA
[4]Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
[5]Eisai Inc., Nutley, NJ, USA
[6]Eisai Co., Ltd, Hatfield, UK
[7]Clario, Philadelphia, PA, USA

The old version of Table 2:

Table 2 Adverse events and ARIA in Clarity Core and Core + OLE

	Core		Core + OLE
	Placebo (N = 897) n/N (%)	**Lecanemab (N = 898) n/N (%)**	**Lecanemab (N = 1612) n/N (%)**
Any adverse event	735 (81.9)	798 (88.9)	1389 (86.2)
Deaths	7 (0.8)	6 (0.7)	16 (1.0)*
Serious adverse event (SAE)	101 (11.3)	126 (14.0)	241 (15.0)
SAE with ARIA-E	0	7 (0.8)	18 (1.1)
SAE with ARIA-H	0	2 (0.2)	10 (0.6)
SAE with infusion-related reactions	0	11 (1.2)	20 (1.2)
Treatment-related adverse event	197 (22.0)	401 (44.7)	721 (44.7)
Adverse event leading to drug withdrawal	26 (2.9)	62 (6.9)	124 (7.7)
ARIA-E	15/897 (1.7)	113/898 (12.6)	219/1612 (13.6)
ARIA-E by ApoE4 genotype			
ApoE4 noncarrier	1/286 (0.3)	15/278 (5.4)	32/496 (6.5)
ApoE4 carrier	14/611 (2.3)	98/620 (15.8)	187/1116 (16.8)
ApoE4 heterozygote	9/478 (1.9)	52/479 (10.9)	101/867 (11.6)
ApoE4 homozygote	5/133 (3.8)	46/141 (32.6)	86/249 (34.5)
Symptomatic ARIA-E	0	25/898 (2.8)	54/1612 (3.3)
ApoE4 noncarrier	0	4/278 (1.4)	8/496 (1.6)
ApoE4 carrier	0	21/620 (3.4)	46/1116 (4.1)
ApoE4 heterozygote	0	8/479 (1.7)	18/867 (2.1)
ApoE4 homozygote	0	13/141 (9.2)	28/249 (11.2)
Recurrent ARIA-E	1 (0.1)	28 (3.1)	46/1612 (2.9)
ApoE4 noncarrier	0/286 (0)	1/278 (0.4)	4/496 (0.8)
ApoE4 carrier	1/611 (0.2)	27/620 (4.4)	42/1116 (11.7)
ApoE4 heterozygote	0/478 (0)	7/479 (1.5)	18/867 (2.1)
ApoE4 homozygote	1/133 (0.8)	20/141 (14.2)	24/249 (9.6)
ARIA-H	80 (8.9)	152 (16.9)	298/1612 (18.5)
Microhemorrhage	68 (7.6)	126 (14.0)	258/1612 (16.0)
Superficial siderosis	21 (2.3)	50 (5.6)	96/1612 (6.0)
Intracerebral hemorrhage	1 (0.1)	5 (0.6)	8/1612 (0.5)
Symptomatic ARIA-H	2 (0.2)	11 (1.2)	27/1612 (1.7)
ARIA-H by ApoE4 genotype			
ApoE4 noncarrier, n/N (%)	11/286 (3.8)	32/278 (11.5)	59/496 (11.9)
ApoE4 carrier, n/N (%)	69/611 (11.3)	120/620 (19.4)	239/1116 (21.4)
ApoE4 heterozygote, n/N (%)	41/478 (8.6)	66/479 (13.8)	140/867 (16.1)
ApoE4 homozygote, n/N (%)	28/133 (21.1)	54/141 (38.3)	99/249 (39.8)
Isolated ARIA-H	69 (7.7)	78 (8.7)	146 (9.1)
Microhemorrhage	63 (7.0)	60 (6.7)	119 (7.4)
Superficial siderosis	13 (1.4)	23 (2.6)	39 (2.4)
Isolated intracerebral hemorrhage	1 (0.1)	4 (0.4)	5 (0.3)
Symptomatic isolated ARIA-H	2 (0.2)	4 (0.4)	6 (0.4)
Isolated ARIA-H by ApoE4 genotype			
ApoE4 noncarrier, n/N (%)	10/286 (3.5)	22/278 (7.9)	38/496 (7.7)
ApoE4 carrier, n/N (%)	59/611 (9.7)	56/620 (9.0)	108/1116 (9.7)
ApoE4 heterozygote, n/N (%)	35/478 (7.3)	39/479 (8.1)	76/867 (8.8)
ApoE4 homozygote, n/N (%)	24/133 (18.0)	17/141 (12.1)	32/249 (12.9)

*The 16 deaths included 6 from Core, 9 from OLE, and one death that occurred > 30 days after last dose

The updated version of Table 2:

Table 2 Adverse events and ARIA in Clarity Core and Core + OLE

	Core		Core + OLE
	Placebo (N = 897) n/N (%)	**Lecanemab (N = 898) n/N (%)**	**Lecanemab (N = 1612) n/N (%)**
Any adverse event	735 (81.9)	798 (88.9)	1389 (86.2)
Deaths	7 (0.8)	6 (0.7)	16 (1.0)*
Serious adverse event (SAE)	101 (11.3)	126 (14.0)	241 (15.0)
SAE with ARIA-E	0	7 (0.8)	18 (1.1)
SAE with ARIA-H	0	2 (0.2)	10 (0.6)
SAE with infusion-related reactions	0	11 (1.2)	20 (1.2)
Treatment-related adverse event	197 (22.0)	401 (44.7)	721 (44.7)
Adverse event leading to drug withdrawal	26 (2.9)	62 (6.9)	124 (7.7)
ARIA-E	15/897 (1.7)	113/898 (12.6)	219/1612 (13.6)
ARIA-E by ApoE4 genotype			
ApoE4 noncarrier	1/286 (0.3)	15/278 (5.4)	32/496 (6.5)
ApoE4 carrier	14/611 (2.3)	98/620 (15.8)	187/1116 (16.8)
ApoE4 heterozygote	9/478 (1.9)	52/479 (10.9)	101/867 (11.6)
ApoE4 homozygote	5/133 (3.8)	46/141 (32.6)	86/249 (34.5)
Symptomatic ARIA-E	0	25/898 (2.8)	54/1612 (3.3)
ApoE4 noncarrier	0	4/278 (1.4)	8/496 (1.6)
ApoE4 carrier	0	21/620 (3.4)	46/1116 (4.1)
ApoE4 heterozygote	0	8/479 (1.7)	18/867 (2.1)
ApoE4 homozygote	0	13/141 (9.2)	28/249 (11.2)
Recurrent ARIA-E	1 (0.1)	28 (3.1)	46/1612 (2.9)
ApoE4 noncarrier	0/286 (0)	1/278 (0.4)	4/496 (0.8)
ApoE4 carrier	1/611 (0.2)	27/620 (4.4)	42/1116 (3.8)
ApoE4 heterozygote	0/478 (0)	7/479 (1.5)	18/867 (2.1)
ApoE4 homozygote	1/133 (0.8)	20/141 (14.2)	24/249 (9.6)
ARIA-H	80 (8.9)	152 (16.9)	298/1612 (18.5)
Microhemorrhage	68 (7.6)	126 (14.0)	258/1612 (16.0)
Superficial siderosis	21 (2.3)	50 (5.6)	96/1612 (6.0)
Intracerebral hemorrhage	1 (0.1)	5 (0.6)	8/1612 (0.5)
Symptomatic ARIA-H	2 (0.2)	11 (1.2)	27/1612 (1.7)
ARIA-H by ApoE4 genotype			
ApoE4 noncarrier, n/N (%)	11/286 (3.8)	32/278 (11.5)	59/496 (11.9)
ApoE4 carrier, n/N (%)	69/611 (11.3)	120/620 (19.4)	239/1116 (21.4)
ApoE4 heterozygote, n/N (%)	41/478 (8.6)	66/479 (13.8)	140/867 (16.1)
ApoE4 homozygote, n/N (%)	28/133 (21.1)	54/141 (38.3)	99/249 (39.8)
Isolated ARIA-H	69 (7.7)	78 (8.7)	146 (9.1)
Microhemorrhage	63 (7.0)	60 (6.7)	119 (7.4)
Superficial siderosis	13 (1.4)	23 (2.6)	39 (2.4)
Isolated intracerebral hemorrhage	1 (0.1)	4 (0.4)	5 (0.3)
Symptomatic isolated ARIA-H	2 (0.2)	4 (0.4)	6 (0.4)
Isolated ARIA-H by ApoE4 genotype			
ApoE4 noncarrier, n/N (%)	10/286 (3.5)	22/278 (7.9)	38/496 (7.7)
ApoE4 carrier, n/N (%)	59/611 (9.7)	56/620 (9.0)	108/1116 (9.7)
ApoE4 heterozygote, n/N (%)	35/478 (7.3)	39/479 (8.1)	76/867 (8.8)
ApoE4 homozygote, n/N (%)	24/133 (18.0)	17/141 (12.1)	32/249 (12.9)

*The 16 deaths included 6 from Core, 9 from OLE, and one death that occurred > 30 days after last dose

The original article [1] has been updated.

Published online: 10 July 2024

References

1. Honig LS, Sabbagh MN, van Dyck CH, et al. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease. Alz Res Therapy. 2024;16:105. https://doi.org/10.1186/s13195-024-01441-8

Publisher's Note